Stathopoulos, P.
Léger, K.
Foege, M.
Lutterotti, A.
Müller, A.
Schanz, U.
Jelcic, I. http://orcid.org/0000-0003-3090-7319
Martin, R. http://orcid.org/0000-0002-0982-1329
Article History
Received: 13 August 2020
Revised: 21 January 2021
Accepted: 18 March 2021
First Online: 6 April 2021
Compliance with ethical standards
:
: Andreas Lutterotti received financial compensation and/or travel support for lectures and advice from Biogen, Merck, Novartis, Teva, Genzyme, Bayer, Celgene, and he is a co-founder and co-owner of Cellerys, a company that pursues antigen-specific tolerization. He is co-inventor on a patent held by the University of Zurich on the use of peptide-coupled cells for treatment of MS. Ilijas Jelcic has received speaker honoraria or unrestricted grants from Biogen Idec and Novartis and has served as advisor for Alexion, Neuway, Merck, Novartis and Sanofi Genzyme. Roland Martin has served as advisor or member of speaker’s boards for Biogen, Novartis, Roche, Genzyme, Teva, Merck-Serono, CellProtect, Neuway and Third Rock Ventures. He is listed as inventor on a UZH-held patent on novel target antigens for MS and is, together with Andreas Lutterotti, a cofounder and co-owner of Cellerys. The group of Roland Martin has received unrestricted grants from Biogen, Novartis and Roche.